Dr. Doug Chapnick is a veteran of cell biology with 20 years’ experience engineering in the life sciences space. He led technology development in the DARPA funded ‘Rapid Threat Assessment (RTA)’ project at the University of Colorado, Boulder. He founded and has raised $10M+ funds for BioLoomics to apply principles from the RTA project to overcome market-wide throughput limitations for activity-based discovery of antibodies. Doug received his PhD in Biochemistry from University of Colorado, Boulder, and has authored over 17 academic research publications ranging in focus from cell biology to drug mechanisms of action.
